The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Third interim analysis from VIsion: ibrutinib/venetoclax in R/R CLL
Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, The Netherlands, discusses the third interim analysis from the phase II VIsion / HO141 trial (NCT03226301). The aim of the trial is to evaluate if combination treatment with venetoclax and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia can lead to MRD-guided treatment cessation and reinitiation. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
